Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia

INCLUSION CRITERIA: Fasting triglycerides * Difference between Visit 3 (7 days prior to Baseline Visit) and Visit 4 (3 days prior to Baseline Visit) ≤ 60% (compared to the higher value of Visit 3 or Visit 4) * Run-in Triglycerides\* ≥ 500 mg/dL and \< 1500 mg/dL \*Run-in Triglyceride is defined as the average fasting triglycerides for Visit 3 (7 days prior to Baseline Visit) and Visit 4 (3 days prior to Baseline Visit). Statin use • Either Statin-naive * Must not be on statin at Screening and remaining as such during the Run-in/Washout Period and throughout the study • Or Statin-treated * Must be on Lipitor 20 mg initiated at the start of the Run-in/Washout Period and continue throughout the study Medication washout * All subjects must be willing to undergo washout of all other lipid-lowering medications Glycemic status * Fasting glucose \< 126 mg/dL at Screening Visit * HbA1c \< 6.5% at Screening Visit EXCLUSION CRITERIA: Medications: recent, current, anticipated * Administration of investigational drugs within 1 month prior to Screening Visit * Thyroid hormones or preparations within 1 month prior to Screening Visit (except in subjects on stable dose of replacement therapy for at least 1 month) * Thiazide diuretics within 2 weeks prior to Screening Visit * Discontinuation of beta-blockers within 1 month prior to Screening Visit or planned discontinuation of beta-blocker therapy * Anticipated requirement for use of prohibited concomitant medications History of allergic reaction or significant intolerance to: * Diazoxide * Thiazides * Sulfonamides * Fenofibrate or fenofibric acid derivatives Lifestyle changes • Subjects intending to change exercise habits, quit smoking and/or quit alcohol use during the entire study Specific diagnoses, medical conditions and history * Known type I or III hyperlipidemia * Known type 1 DM * Current diagnosis of type 2 DM * Any other clinically significant endocrine, cardiovascular, pulmonary, neurological, psychiatric, hepatic, gastrointestinal, hematological, renal, or dermatological disease interfering with the assessments of the study medications, according to the Investigator Specific laboratory test results • Any relevant biochemical abnormality interfering with the assessments of the study medications